Joshua E. Schimmer

Biogen Is A Frustrating Case, And Piper Jaffray Hopes It Doesn't Regret Upgrade

Biogen Drug 'Increasingly Vulnerable,' Analyst Warns After Speaking With MS Expert

MannKind's Future Looks 'Grim,' Has 37% Downside Warns Piper Jaffray

Biogen Drug 'Increasingly Vulnerable,' Analyst Warns After Speaking With MS Expert

MannKind's Future Looks 'Grim,' Has 37% Downside Warns Piper Jaffray

ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray

Analyst Sees Upside To Outlook At 4 Biotechs

ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray

Analyst Sees Upside To Outlook At 4 Biotechs

UPDATE: Piper Jaffray Initiates Coverage On Lion Biotechnologies Based On DCF Analysis

UPDATE: Piper Jaffray Upgrades ISIS Pharmaceuticals Following Mixed 1Q Results

Joshua E. Schimmer Recent News

UPDATE: Piper Jaffray Initiates Coverage on Regeneron Pharmaceuticals as 2014 Biotech Sector Outlook Remains Strong

UPDATE: Piper Jaffray Initiates Coverage on Vanda Pharmaceuticals on Expected Attractive Returns

UPDATE: Piper Jaffray Initiates Coverage on Pharmacyclics as 2014 Biotech Sector Outlook Remains Strong

UPDATE: Piper Jaffray Initiates Coverage on MannKind on Expected Attractive Returns

UPDATE: Piper Jaffray Initiates Coverage on Incyte as 2014 Biotech Sector Outlook Remains Strong

UPDATE: Piper Jaffray Initiates Coverage on Gilead Sciences on Expected Attractive Returns

UPDATE: Piper Jaffray Resumes Coverage on Celgene as 2014 Biotech Sector Outlook Remains Strong

UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical on Expected Attractive Returns

UPDATE: Piper Jaffray Resumes Coverage on Biogen Idec as 2014 Biotech Sector Outlook Remains Strong

UPDATE: Piper Jaffray Initiates Coverage on Amgen on Expected Attractive Returns

UPDATE: Piper Jaffray Initiates Coverage on Alexion Pharmaceuticals as 2014 Biotech Sector Outlook Remains Strong

UPDATE: Piper Jaffray Initiates Coverage on Nektar Therapeutics on Expected Attractive Returns

UPDATE: Piper Jaffray Initiates Coverage on Insmed as 2014 Biotech Sector Outlook Remains Strong

UPDATE: Piper Jaffray Initiates Coverage on GW Pharmaceuticals on Expected Attractive Returns

UPDATE: Piper Jaffray Initiates Coverage on Chimerix as 2014 Biotech Sector Outlook Remains Strong

UPDATE: Piper Jaffray Initiates Coverage on Repros Therapeutics on a Cleaner Approach to Male Hypogonadism

UPDATE: Piper Jaffray Assumes Coverage on ISIS Pharmaceuticals as Company's Antisense Platform Continues to Advance